Indeed, oral anti-platelet agents are promptly prescribed to reduce the risk of local thrombotic complications and systemic ischemic events, while angiotensin-converting enzyme (ACE) inhibitors and β-blockers are useful to improve outcomes in post-AMI patients complicated by heart failure, diabetes, and/or hypertension [2]. Here, ACE is linked to diabetes mellitus.